MBMEDBT@EC2607A

JPMorgan Maintains Overweight Rating on MicroPort Surgical with Price Target

MicroPort Surgical's Toumai® Laparoscopic Surgical Robot System Receives Over 200 Orders

Micro-Innovation Robot Announces FY Revenue Growth Exceeding 100%

JPMorgan Downgrades MicroPort Surgical's 2025 Sales Forecast, Maintains 'Overweight' Rating

Microbot Medical-B Sees Adjusted Net Loss Narrowing Sharply

MicroPort Surgical Robots Forecasts 110%-120% Revenue Growth in 2025

MicroPort Robotics Completes the World's First Animal Experiment of Large Model Autonomous Surgery

Medical Biotechnology Sector Returns Down, Breakthroughs in Brain-Computer Interfaces and Surgical Robots

MicroPort Surgical's Bronchoscopy Robot Receives NMPA Approval

MicroPort Surgical Robots Core Products Orders Exceed 230 Units

Micro-Innovation Surgical Robots' Bronchoscopy Robot Approved by NMPA

MicroPort Surgical Robot's Tumie Global Orders Exceed 160 Units

Chinese surgical robot companies achieve positive progress in overseas sales

JPMorgan Raises MicroPort Surgical Target Price to HKD 42 and Reiterates Overweight Rating

Analyst Choi Strongly Recommends MicroPort Surgical H Shares

MicroPort Surgical Robot Orders Exceed 170 Globally

JPMorgan Upgrades MicroPort Surgical Machine to Buy

JPMorgan Raises Target Price and Rating for Minivasive Robotics

Citi Raises Target Price for MicroPort Surgical to HKD 32

MicroPort Robotics-B Reports 77% Revenue Growth and Reduced Losses in H1 2025

HKC INT'L RTS

TIANBAO ENERGY

SUMMI

HANG YICK RTS

UNI PRINTSHOP

CHERISH SUN

NE ELECTRIC

SINO GAS HLDGS

MANY IDEA CLOUD

CREATIVE CHINA

02252

MicroPort Medbot has received approval from the Stock Exchange for the listing and trading of 5,989,800 H shares. The conversion and listing will involve a total of 5,989,800 unlisted shares held by two shareholders of the company, accounting for approximately 0.5808% of the company's total issued shares

AASTOCKS

MircroPort Medbot-B

MicroPort Medbot has received approval for nearly 6 million shares for full circulation of H shares

02513

01757

00600

02546

00100

09903

02587

00658

02659

KNOWLEDGE ATLAS(02513) rose 20.65%, with a trading turnover 2.4 Billion HKD, and a year-to-date rose 317.4%. AFFLUENT FDN(01757) rose 18.63%, with a trading turnover 22.2 Million HKD, and a year-to-date rose 221.5%. AXERA(00600) rose 17.16%, with a trading turnover 186.3 Million HKD, and a year-to-date rose 0.2%.

Top Gainers & Losers

KNOWLEDGE ATLAS

AFFLUENT FDN

AXERA

ZHIHUI MINING

MINIMAX-WP

ILUVATAR COREX

HEALTHYWAY INC

C TRANSMISSION

BAO PHARMA-B

Top 10 HK Stock Gainers (2.13)

159898

562600

JP Morgan released a report stating that MicroPort Medbot's core product "TUMAI" has surpassed 200 orders, demonstrating strong market demand. The product's coverage has expanded to over 50 countries, particularly performing well in emerging markets such as India and Brazil. JP Morgan maintains an "Overweight" rating on MicroPort Medbot with a target price of 41 yuan, believing it will benefit from the trend of import substitution

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

"Big Banks" JP Morgan: MicroPort Medbot's overseas expansion accelerates, maintains "Overweight" rating

02172

00853

02160

MicroPort CardioFlow has merged with MicroPort CRM to create a comprehensive platform focused on structural heart, cardiac rhythm management, and heart failure. This merger aims to enhance access to advanced cardiovascular technologies globally. The original content was published by MicroPort Scientific Corporation on February 10, 2026.

Reuters

MICROPORT NEURO

MICROPORT

MP CARDIOFLOW-B

MicroPort CardioFlow Merges with MicroPort CRM

06600

09988

CLOU

BABA

300024

Alibaba Cloud Computing invested in the variable robotics technology company, increasing its registered capital to 978,100 yuan. The company was established in 2023, with Wang Qian as the legal representative. Its business scope includes the research and sales of intelligent robots, as well as artificial intelligence-related services

Wallstreetcn

ONEROBOTICS

BABA-W

Global X Cloud Computing ETF

Alibaba

SIASUN

Alibaba Cloud Computing invests in Variable Robotics Technology Company

GXAI

Due to the temporary suspension of short selling by the U.S. government, the non-farm payroll and CPI will be released in the same week, raising concerns about the combination of "weak employment + strong inflation." Domestically, January's social financing and inflation data will be released to verify the economic "good start." The Spring Festival will be a key window for AI promotion, with giants like Alibaba and ByteDance launching a "red envelope war," and Yush Robot set to appear on the Spring Festival Gala, while new models like DeepSeek and Grok are gearing up. The focus of financial reports will be on SMIC, NetEase, and recently hard-hit software stocks. Additionally, the U.S. and Iran are set to engage in a new round of negotiations

- The week of February 9 to February 15 will witness significant economic events, with a focus on U.S. and China inflation data and imminent releases of non-farm payroll and CPI reports amidst market uncertainties.  
- Major companies in the technology sector are intensifying competition during the Spring Festival, with significant investments in AI applications and anticipated IPOs from semiconductor firms.  
- Geopolitical tensions are increasing, particularly with the U.S. planning new negotiations with Iran, while fluctuations in the precious metals market are expected due to upcoming margin adjustments.

C3.AI

Gaxos.ai

Virtus Artificial Intelligence & Tech Opportunities Fd

NETEASE MUSIC

SMIC

NTES-S

NetEase

YieldMax AI Option Income Strategy ETF

Next week's heavy schedule: US Non-Farm Payrolls and CPI release, China's inflation, AI and robotics Spring Festival battle

Shanghai MicroPort MedBot (Group) Co., Ltd. has received approval from the CSRC to convert 5,989,798 previously unlisted shares into H shares, representing 0.58% of its total share capital. This move is part of the company's plan to enhance liquidity and broaden its shareholder base on the Hong Kong Main Board. The stock currently holds a Hold rating with a price target of HK$31.00. The company specializes in medical robotics and aims to expand its presence in the Hong Kong capital market.

Tip Ranks

MicroPort MedBot Gains CSRC Nod for 5.99 Million H-Share Conversion

02675

Zhejiang Merchants Securities research report states that with the implementation of the medical insurance bureau's charging catalog policy and the accelerated expansion of overseas markets, the industry is expected to transition from the early development stage to a rapid growth phase. The medical insurance bureau's charging catalog policy will be implemented in 2026, clearly defining the charging framework for four types of robots, which will significantly lower the admission threshold. Leading companies such as MicroPort and EDGE MEDICAL are experiencing rapid growth in overseas orders, making overseas expansion a new engine for growth. It is expected that by 2032, the market size of surgical robots in China will surge from 7.2 billion yuan in 2024 to 76.7 billion yuan, with a compound annual growth rate of 34%

- The domestic surgical robot industry is transitioning from "concept validation" to "scaled profitability," with a predicted market size of approximately 72 billion RMB in 2024, growing to 767 billion RMB by 2032.  
- Key drivers include the recent national healthcare reimbursement guidelines and increasing overseas orders, indicating a significant market opportunity with a compound annual growth rate (CAGR) of about 34%.  
- The 2026 policy implementation is anticipated to address previous economic concerns for hospitals, facilitating accelerated adoption and supporting greater commercial success for domestic firms.

EDGE MEDICAL-B

How far have domestic surgical robots come?

688351

688016

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

MICROPORT EP

Endovastec

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

MBMEDBT@EC2607A(24638.HK)

MicroPort Medbot has received approval for nearly 6 million shares for full circulation of H shares

Top 10 HK Stock Gainers (2.13)

"Big Banks" JP Morgan: MicroPort Medbot's overseas expansion accelerates, maintains "Overweight" rating

MicroPort CardioFlow Merges with MicroPort CRM

Alibaba Cloud Computing invests in Variable Robotics Technology Company